NEW YORK, Sept. 18, 2023 /PRNewswire/ — The breast cancer monoclonal antibodies market is expected to grow by USD 15 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 12.5% during the forecast period, according to Technavio Research. The market has been segmented by end-user (hospitals, research institutes, and others), type (humanized, human, chimeric, and murine), and Geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 42% to the growth of the global market during the forecast period. Advances in technology and the increasing incidence of breast cancer have increased the demand for monoclonal antibodies in the region. The key factors driving the market growth in this region are the increasing adoption of personalized medicine, the need for early detection of breast cancer, and the development of targeted therapies. In addition, North America has a strong healthcare infrastructure, genomic expertise, and broad access to monoclonal antibodies. Regional medical organizations focus on targeted therapies to treat many types of cancer, including breast cancer. This has led to the need for personalized medicine and the development of related monoclonal antibodies. Hence, these factors are expected to drive market growth during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read FREE PDF Sample Report
Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Amgen Inc. – The company offers breast cancer monoclonal antibodies such as KANJINTI.
To gain access to more vendor profiles available with Technavio, buy the report!
Breast Cancer Monoclonal Antibodies Market: Segmentation Analysis
The market share growth by the hospitals segment will be significant during the forecast period. Hospitals play an important role in the diagnosis, treatment, and management of breast cancer. Furthermore, hospitals often serve as primary centers for breast cancer diagnosis. As part of breast cancer treatment plans, hospitals provide monoclonal antibody drug therapy directly to patients.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a FREE PDF Sample Report
“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio
Breast Cancer Monoclonal Antibodies Market
- Increasing demand for minimally invasive therapies for breast cancer treatment
- Increasing prevalence of breast cancer
- Rising number of patient support initiatives for breast cancer awareness
Increasing demand for minimally invasive therapies for breast cancer treatment is a key factor driving market growth. Minimally invasive therapies, such as targeted monoclonal antibody therapy, are gaining prominence due to their potential to provide effective, less invasive treatments with fewer side effects. Minimally invasive treatment, including monoclonal antibody therapy targeting specific tumor cells or molecules and causing minimal damage to healthy tissues, is more effective than traditional chemotherapeutics or surgical procedures. In addition, the key factors driving the development of minimally invasive therapies are shorter hospital stays, reduced pain and discomfort, and faster recovery. Breast cancer patients are primarily looking for alternatives to traditional treatments that often include more invasive procedures, longer hospital stays, and extended recovery times. Hence, these factors are expected to drive market growth during the forecast period.
The growing number of strategic collaborations is a major trend in the breast cancer monoclonal antibodies market. Identify key trends, drivers, and challenges in the market. Download FREE sample to gain access to this information.
The photodynamic therapy market is estimated to grow by USD 2,053.68 million at a CAGR of 8.22% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by application (cancer, actinic keratosis, psoriasis, acne, and others), product (photosensitizer drugs, and photodynamic therapy devices), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Early detection of cancer is a key factor driving market growth during the forecast period.
The hereditary angioedema (HAE) therapeutics market is estimated to grow by USD 1,647.38 million at a CAGR of 8.95% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by end-user (hospital pharmacies, retail pharmacies, and e-commerce), product (C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others), geography (North America, Europe, Asia, and the Rest of the World (ROW)). The growing demand for personalized medicine is a major trend in the market.
- How do the major trends impact the market?
- How big is the North America market?
- How do the key drivers and challenges impact the market?
Historic Market Sizes
Five Forces Analysis
Market Segmentation by End-User
Market Segmentation by Type
Market Segmentation by Geography
Drivers, Challenges, & Trends
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.